Company: STAA
Filing Date: 2025-10-02
Form Type: DFAN14A
Source: 0001213900-25-095514
Chunk: 21

Company: STAAR SURGICAL CO
Filing Date: 2025-10-02
Form: DFAN14A
Chunk 21
---
,000 ICL Cases Redefined Myopia Treatment in Aier ,” presented at the STAAR Surgical Symposium, April 26, 2025. 1.4 2.0 2.6 3.4 4.1 4.8 0.2 0.3 0.4 0.5 0.7 1.0 1.6 2.2 3.0 3.9 4.8 5.7 0% 10% 20% 30% 40% 50% 60% 70% 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 2000 2010 2020 2030 2040 2050 Prevalence of Myopia in Population Expected Cases of Myopia (in Billions) Myopia High Myopia Prevalence (Myopia) Prevalence (High Myopia) 3 B

Broadwood Partners, L.P. ICLs Enjoy Significant Benefits Over Other Refractive Procedures… 29 We believe ICLs are the clear choice in vision correction Source: STAAR Investor Presentation, filed with the SEC on June 4, 2025. SMILE PRK LASIK EVO / EVO+ ICL Safety Features Reversible Treats eyes with thin cornea UV protection Long history of use Vision Quality Sharp and clear vision Ability to correct higher myopia Patient Experience 20 - 30 minute outpatient procedure Widely available No corneal tissue removed Limited patient discomfort during recovery Lower likelihood of dry eye syndrome 4 B

Broadwood Partners, L.P. Lines of Improvement on a Standard Eye Chart with EVO ICLs vs. Prior Corrective Solution 1 …And Recent Data Indicate that ICLs May Become the Dominant Choice 30 We believe ICLs are superior to other refractive procedures and will continue to take market share 1. Source: Roger Zaldivar, Roberto Zaldivar, Carlos Gordillo and Pablo Adamek, “Visual Acuity Improvement in Low, Moderate and H igh Myopia After Posterior - Chamber Phakic Implantable Collamer Lens Surgery in a Large Patient Cohort,” Clinical Ophthalmology , April 2023,17:1179 - 1185. 2. Source: Jesper Hjortdal, ESCRS